SC 102 - Scotia

Drug Profile

SC 102 - Scotia

Latest Information Update: 04 Jul 2000

Price : $50

At a glance

  • Originator QuantaNova
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Photosensitisers; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 04 Jul 2000 Discontinued-Preclinical for Cancer in United Kingdom (Unknown route)
  • 14 Jul 1998 Profile reviewed
  • 02 Aug 1995 Preclinical development for Cancer in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top